RT Journal
A1 Gulløv AL, Koefoed BG, Petersen P, et al
T1 WArfarin vs aspirin and afasak 2
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1999
FD May 10
VO 159
IS 9
SP 1010
OP 1010
DO 
UL http://dx.doi.org/
AB 
We thank Dr Bloom for his comments about the AFASAK 2 study we published.1 As commented on by Bloom, the cumulative risk for thromboembolic events in patients treated with aspirin, 300 mg/d, in the AFASAK 2 study was very close to that for patients receiving adjusted-dose warfarin sodium internationalized normal ratio of 2:3 (3.6% vs 2.8% after 1 year and 8.4% vs 8.3% after 3, respectively). However, the corresponding event rates in patients receiving aspirin, 300 mg/d, plus warfarin sodium, 1.25 mg/d, were 7.2% and 12.8%, respectively, and in patients receiving warfarin sodium, 1.25 mg/d, 5.8% and 11.9%, respectively. By comparing the cumulative event rates, no significant difference was found (P=.67) between the 4 study groups.